Cargando…
Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535565/ https://www.ncbi.nlm.nih.gov/pubmed/35754288 http://dx.doi.org/10.3233/JPD-223201 |
_version_ | 1784802798576074752 |
---|---|
author | Janzen, Annette Vadasz, David Booij, Jan Luster, Markus Librizzi, Damiano Henrich, Martin T. Timmermann, Lars Habibi, Mahboubeh Sittig, Elisabeth Mayer, Geert Geibl, Fanni Oertel, Wolfgang |
author_facet | Janzen, Annette Vadasz, David Booij, Jan Luster, Markus Librizzi, Damiano Henrich, Martin T. Timmermann, Lars Habibi, Mahboubeh Sittig, Elisabeth Mayer, Geert Geibl, Fanni Oertel, Wolfgang |
author_sort | Janzen, Annette |
collection | PubMed |
description | BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [(123)I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([(123)I]FP-CIT-SPECT)— for identifying iRBD patients as prodromal phenotype of PD/DLB. METHODS: 37 RBD subjects underwent cardiac [(123)I]MIBG and brain [(123)I]FP-CIT-SPECT at baseline. Olfactory (Sniffin’ Sticks), cognitive and motor functions were tested annually for ∼4 years. RESULTS: 29/37 (78.4%) subjects had a pathological [(123)I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [(123)I]FP-CIT-SPECT, always combined with a pathological [(123)I]MIBG. In subjects with pathological [(123)I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [(123)I]MIBG compared to those with normal [(123)I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [(123)I]MIBG and [(123)I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all— except for one— presented with at least moderate hyposmia at baseline. CONCLUSION: A combination of the biomarkers “pathological [(123)I]MIBG” and “hyposmia” likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [(123)I]MIBG had a normal [(123)I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [(123)I]MIBG, olfactory impairment is progressive independent of the [(123)I]FP-CIT-SPECT status. |
format | Online Article Text |
id | pubmed-9535565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95355652022-10-20 Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder Janzen, Annette Vadasz, David Booij, Jan Luster, Markus Librizzi, Damiano Henrich, Martin T. Timmermann, Lars Habibi, Mahboubeh Sittig, Elisabeth Mayer, Geert Geibl, Fanni Oertel, Wolfgang J Parkinsons Dis Research Report BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [(123)I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([(123)I]FP-CIT-SPECT)— for identifying iRBD patients as prodromal phenotype of PD/DLB. METHODS: 37 RBD subjects underwent cardiac [(123)I]MIBG and brain [(123)I]FP-CIT-SPECT at baseline. Olfactory (Sniffin’ Sticks), cognitive and motor functions were tested annually for ∼4 years. RESULTS: 29/37 (78.4%) subjects had a pathological [(123)I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [(123)I]FP-CIT-SPECT, always combined with a pathological [(123)I]MIBG. In subjects with pathological [(123)I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [(123)I]MIBG compared to those with normal [(123)I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [(123)I]MIBG and [(123)I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all— except for one— presented with at least moderate hyposmia at baseline. CONCLUSION: A combination of the biomarkers “pathological [(123)I]MIBG” and “hyposmia” likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [(123)I]MIBG had a normal [(123)I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [(123)I]MIBG, olfactory impairment is progressive independent of the [(123)I]FP-CIT-SPECT status. IOS Press 2022-09-02 /pmc/articles/PMC9535565/ /pubmed/35754288 http://dx.doi.org/10.3233/JPD-223201 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Report Janzen, Annette Vadasz, David Booij, Jan Luster, Markus Librizzi, Damiano Henrich, Martin T. Timmermann, Lars Habibi, Mahboubeh Sittig, Elisabeth Mayer, Geert Geibl, Fanni Oertel, Wolfgang Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder |
title | Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder |
title_full | Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder |
title_fullStr | Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder |
title_full_unstemmed | Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder |
title_short | Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder |
title_sort | progressive olfactory impairment and cardiac sympathetic denervation in rem sleep behavior disorder |
topic | Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535565/ https://www.ncbi.nlm.nih.gov/pubmed/35754288 http://dx.doi.org/10.3233/JPD-223201 |
work_keys_str_mv | AT janzenannette progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT vadaszdavid progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT booijjan progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT lustermarkus progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT librizzidamiano progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT henrichmartint progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT timmermannlars progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT habibimahboubeh progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT sittigelisabeth progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT mayergeert progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT geiblfanni progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder AT oertelwolfgang progressiveolfactoryimpairmentandcardiacsympatheticdenervationinremsleepbehaviordisorder |